Physician profile
Thomas E Lyles
NPI 1841410024
$8,433.51
in general payments reported to CMS, 2019-2025
39 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $643 · 2021: $1,463 · 2022: $1,237 · 2023: $1,388 · 2024: $1,677 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,133.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,881.03 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $911.29 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $753.32 | 2019-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $422.80 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $323.12 | 2021-2023 | Zeposia |
| Pfizer INC. | $312.70 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $304.79 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $279.32 | 2023-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $184.31 | 2020-2023 | Linzess |
| Lilly USA, LLC | $167.58 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $163.34 | 2022-2024 | Ibsrela |
| Redhill Biopharma INC. | $159.35 | 2021-2023 | Talicia |
| Amgen INC. | $136.31 | 2021-2023 | Amjevita, Avsola |
| Phathom Pharmaceuticals, INC. | $105.88 | 2024-2025 | Voquezna |
| Mauna Kea Technologies, INC. | $100.95 | 2019-2020 |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$29,007.39 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lyles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.